Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

SIMPLE SUMMARY: Despite the relationship between Carfilzomib (CFZ) therapy in multiple myeloma (MM) and cardiovascular adverse events (CVAEs), no specific validated protocols on cardiovascular risk assessment are available. In this prospective study, we investigated major predictors of CVAEs prior t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Vallelonga, Fabrizio, Covella, Michele, Catarinella, Cinzia, Cesareo, Marco, Bruno, Giulia, Leone, Dario, Giordana, Carlo, Cetani, Giusy, Salvini, Marco, Gay, Francesca, Bringhen, Sara, Rabbia, Franco, Veglio, Franco, Milan, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036868/
https://ncbi.nlm.nih.gov/pubmed/33915804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13071631
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados